S

Standard BioTools Inc. (LAB)

NMS – Real vaqt narxi. Valyuta: USD

1.01

+0.02 (2.02%)

Yopilishda: May 12, 2026, 4:00 PM EDT

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Barcha huquqlar himoyalangan.

Foydalanish shartlari

S

Standard BioTools Inc. (LAB)

NMS – Real vaqt narxi. Valyuta: USD

1.01

+0.02 (2.02%)

Yopilishda: May 12, 2026, 4:00 PM EDT

06.05.2026

Standard BioTools (LAB) Reports Q1 Loss, Tops Revenue Estimates

Standard BioTools (LAB) came out with a quarterly loss of $0.02 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.04 per share a year ago.

05.05.2026

Standard BioTools Reports First Quarter 2026 Financial Results

BOSTON, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the quarter ended March 31, 2026.

24.02.2026

Standard BioTools Reports Fourth Quarter and Full Year 2025 Financial Results

BOSTON, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the quarter and fiscal year ended December 31, 2025.

10.02.2026

Standard BioTools to Announce Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026

BOSTON, Mass., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that it will publish fourth quarter and full year 2025 financial results on Tuesday, February 24, 2026, after U.S. market close.

30.01.2026

Standard BioTools Completes Sale of SomaLogic to Illumina

Received $350 Million in upfront cash at closing; Up to $425 Million in total proceeds inclusive of near-term earnout payments

08.01.2026

Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2025 Revenue

BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (“Standard BioTools” or the “Company”) today announced preliminary and unaudited revenue results for the fourth quarter and full year 2025. Standard BioTools expects fourth quarter 2025 combined company revenue of approximately $56 million and revenue from continuing operations of approximately $24 million.

19.11.2025

Molecular Instruments and Standard BioTools Announce Collaboration to Bring Amplified Multi-Omic Readouts to Imaging Mass Cytometry

LOS ANGELES & SAN FRANCISCO--(BUSINESS WIRE)-- #Biotech--MI & Standard BioTools integrate HCR™ Gold with the Hyperion™ Imaging System to enable amplified RNA and protein detection for Imaging Mass Cytometry.

Videolar

No Data

There is no data to display

Press-relizlar

05.05.2026

Standard BioTools Reports First Quarter 2026 Financial Results

BOSTON, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the quarter ended March 31, 2026.

24.02.2026

Standard BioTools Reports Fourth Quarter and Full Year 2025 Financial Results

BOSTON, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the quarter and fiscal year ended December 31, 2025.

30.01.2026

Standard BioTools Completes Sale of SomaLogic to Illumina

Received $350 Million in upfront cash at closing; Up to $425 Million in total proceeds inclusive of near-term earnout payments

08.01.2026

Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2025 Revenue

BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (“Standard BioTools” or the “Company”) today announced preliminary and unaudited revenue results for the fourth quarter and full year 2025. Standard BioTools expects fourth quarter 2025 combined company revenue of approximately $56 million and revenue from continuing operations of approximately $24 million.

Search stocks

Standard BioTools Inc. (LAB)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Standard BioTools Inc. (LAB)

Standard BioTools (LAB) Reports Q1 Loss, Tops Revenue Estimates

Standard BioTools Reports First Quarter 2026 Financial Results

Standard BioTools Reports Fourth Quarter and Full Year 2025 Financial Results

Standard BioTools to Announce Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026

Standard BioTools Completes Sale of SomaLogic to Illumina

Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2025 Revenue

Molecular Instruments and Standard BioTools Announce Collaboration to Bring Amplified Multi-Omic Readouts to Imaging Mass Cytometry

Videolar

No Data

Press-relizlar

Standard BioTools Reports First Quarter 2026 Financial Results

Standard BioTools Reports Fourth Quarter and Full Year 2025 Financial Results

Standard BioTools Completes Sale of SomaLogic to Illumina

Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2025 Revenue